Advertisement

Pharmacotherapy of Tricuspid Valve Disease

  • Kadir CaliskanEmail author

Abstract

In this section, pharmacological treatment of tricuspid regurgitation will be revised and illustrated by a case of patient with severe tricuspid regurgitation. The basic approach of pharmacological treatment of tricuspid valve disease is the treatment of volume overload/congestion, pulmonary hypertension and support of the right ventricle.

Keywords

Tricuspid Regurgitation Heart failure Pharmacotherapy Outcome 

Supplementary material

Video S1

(MP4 295 kb)

Video S2

(MP4 274 kb)

Video S3

(MP4 429 kb)

Video S4

(MP4 355 kb)

References

  1. 1.
    Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(23):2440–92.CrossRefPubMedGoogle Scholar
  2. 2.
    Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):1810–52.CrossRefPubMedGoogle Scholar
  3. 3.
    Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891–975.CrossRefPubMedGoogle Scholar
  4. 4.
    Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341(10):709–17.CrossRefPubMedGoogle Scholar
  5. 5.
    Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364(1):11–21.CrossRefPubMedGoogle Scholar
  6. 6.
    McMahon WS, Holzgrefe HH, Walker JD, Mukherjee R, Arthur SR, Cavallo MJ, et al. Cellular basis for improved left ventricular pump function after digoxin therapy in experimental left ventricular failure. J Am Coll Cardiol. 1996;28(2):495–505.CrossRefPubMedGoogle Scholar
  7. 7.
    Rathore SS, Curtis JP, Wang Y, Bristow MR, Krumholz HM. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289(7):871–8.CrossRefPubMedGoogle Scholar
  8. 8.
    The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril wSurvival Study (CONSENSUS). N Engl J Med. 1987;316(23):1429–35.CrossRefGoogle Scholar
  9. 9.
    Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353(9169):2001–7.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  1. 1.Thoraxcenter, Department of CardiologyErasmus MC University Medical CenterRotterdamThe Netherlands

Personalised recommendations